MIRM – mirum pharmaceuticals, inc. - common stock (US:NASDAQ)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

YTD

1 Day

MIRM

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

12/11

09:04 am

mirm

Mirum Pharmaceuticals (NASDAQ:MIRM) had its "strong-buy" rating reaffirmed by analysts at Raymond James Financial, Inc..

Low Report

Mirum Pharmaceuticals (NASDAQ:MIRM) had its "strong-buy" rating reaffirmed by analysts at Raymond James Financial, Inc..

Report

12/10

05:04 pm

mirm

Mirum Pharmaceuticals (NASDAQ:MIRM) had its "outperform" rating reaffirmed by analysts at Leerink Partners.

Low Report

Mirum Pharmaceuticals (NASDAQ:MIRM) had its "outperform" rating reaffirmed by analysts at Leerink Partners.

Report

12/9

12:17 pm

mirm

Rating for MIRM

Low Report

Rating for MIRM

Report

12/9

12:17 pm

mirm

Rating for MIRM

Low Report

Rating for MIRM

Report

12/9

11:45 am

mirm

Rating for MIRM

Low Report

Rating for MIRM

Report

12/9

11:45 am

mirm

Rating for MIRM

Low Report

Rating for MIRM

Report

12/9

10:29 am

mirm

Rating for MIRM

Low Report

Rating for MIRM

Report

12/9

09:11 am

mirm

Mirum Pharmaceuticals (NASDAQ:MIRM) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.

Medium Report

Mirum Pharmaceuticals (NASDAQ:MIRM) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.

Report

12/9

09:11 am

mirm

Mirum Pharmaceuticals (NASDAQ:MIRM) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.

Medium Report

Mirum Pharmaceuticals (NASDAQ:MIRM) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.

Report

12/8

06:07 pm

mirm

Mirum Pharmaceuticals (NASDAQ:MIRM) had its "outperform" rating reaffirmed by analysts at Evercore ISI.

Medium Report

Mirum Pharmaceuticals (NASDAQ:MIRM) had its "outperform" rating reaffirmed by analysts at Evercore ISI.

Report

12/8

06:07 pm

mirm

Mirum Pharmaceuticals (NASDAQ:MIRM) had its "outperform" rating reaffirmed by analysts at Evercore ISI.

Medium Report

Mirum Pharmaceuticals (NASDAQ:MIRM) had its "outperform" rating reaffirmed by analysts at Evercore ISI.

Report

12/8

11:01 am

mirm

Mirum Pharmaceuticals (NASDAQ:MIRM) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.

Low Report

Mirum Pharmaceuticals (NASDAQ:MIRM) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.

Report

11/5

11:07 am

mirm

Rating for MIRM

Low Report

Rating for MIRM

Report

11/5

10:03 am

mirm

Mirum Pharmaceuticals (NASDAQ:MIRM) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.

Low Report

Mirum Pharmaceuticals (NASDAQ:MIRM) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.

Report

11/5

07:19 am

mirm

Mirum Pharmaceuticals (NASDAQ:MIRM) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..

Low Report

Mirum Pharmaceuticals (NASDAQ:MIRM) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..

Report

11/5

07:19 am

mirm

Mirum Pharmaceuticals (NASDAQ:MIRM) had its "buy" rating reaffirmed by analysts at HC Wainwright.

Low Report

Mirum Pharmaceuticals (NASDAQ:MIRM) had its "buy" rating reaffirmed by analysts at HC Wainwright.

Report

10/16

01:59 pm

mirm

Rating for MIRM

Low Report

Rating for MIRM

Report

10/16

01:59 pm

mirm

Rating for MIRM

Low Report

Rating for MIRM

Report

10/16

09:06 am

mirm

Mirum Pharmaceuticals (NASDAQ:MIRM) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.

Low Report

Mirum Pharmaceuticals (NASDAQ:MIRM) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.

Report

10/16

09:06 am

mirm

Mirum Pharmaceuticals (NASDAQ:MIRM) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.

Low Report

Mirum Pharmaceuticals (NASDAQ:MIRM) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.

Report

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.